¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01
±³À°ÀÏÀÚ : 2023-04-01
±³À°Àå¼Ò : ¼­¿ïµå·¡°ï½ÃƼ ÄÁº¥¼Ç¼¾ÅÍ 3Ãþ ÇѶóȦ

±³À°ÁÖÁ¦ : 2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA)

ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ
´ã´çÀÚ : 2023 SoLA Áغñ»ç¹«±¹
¿¬¶ôó : 02-6734-1011  

À̸ÞÀÏ : sola2023@planbear.co.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 70,000¿ø  

ºñ°í ±³¼ö, °³¿øÀÇ, ºÀÁ÷ÀÇ È¸¿ø »çÀüµî·Ï 40,000¿ø/ÇöÀåµî·Ï 50,000¿ø,ºñȸ¿ø »çÀüµî·Ï 60,000¿ø/ ÇöÀåµî·Ï 70,000¿øÀüÀÓÀÇ, ¿µ¾ç»ç, ¿îµ¿»ç, °£È£»ç, ¿¬±¸¿ø ¹× ±âŸ Âü°¡ÀÚȸ¿ø »çÀüµî·Ï 20,000¿ø/ÇöÀåµî·Ï 30,000¿øºñȸ¿ø »çÀüµî·Ï 40,000¿ø/ÇöÀåµî·Ï 50,000¿ø Àü°øÀÇ, Çлý, ±ºÀÇ°ü, °øÁߺ¸°ÇÀÇ, 65¼¼ ÀÌ»ó ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 07:30~08:30 Combination therapy of ezetimibe and atorvastatin for dyslipidemia ±èÇý°æ(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 08:30~08:50 Triglyceride lowering with pemafibrate to reduce cardiovascular risk ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 08:50~09:10 Lipoprotein(a) reduction in persons with cardiovascular disease ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 09:10~09:30 A comparison of two LDL cholesterol targets after Ischemic stroke ±è¹üÁØ(¿ï»êÀÇ´ë ½Å°æ°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 09:30~10:00 Panel discussion ()

ÈÞ½Ä 04-01 ÇѶóȦ Room1 10:00~10:15 Break ()

±âŸ 04-01 ÇѶóȦ Room1 10:15~10:20 Opening address ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 10:20~11:00 Past and prospect of atherosclerosis therapy ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)

ÈÞ½Ä 04-01 ÇѶóȦ Room1 11:00~12:00 Coffee break & Poster viewing ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 12:00~13:00 Cutting edge care of pitavastatin with ezetimibe combination therapy È«ÁØÈ­(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 12:00~13:00 Atorvastatin/Ezetimibe treatment for the dyslipidemia in diabetic patients ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 13:00~13:20 Pros À̼ö¿ë(ºÎ»êÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 13:20~13:40 Cons ÇѼº¸²(¼­¿ï´ë ½ÄÇ°¿µ¾çÇаú)

Åä·Ð 04-01 ÇѶóȦ Room1 13:40~13:50 Rebuttal ()

Åä·Ð 04-01 ÇѶóȦ Room1 13:50~14:30 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:00~13:20 A potential therapeutic target for atherosclerotic calcification ÃÖÀçÈÆ(ÇѾç´ë »ý¸í°úÇаú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:20~13:40 Vasoprotective role of angiogenic adipokine ÇÏâÈÆ(¿ï»êÀÇ´ë À¶ÇÕÀÇÇаú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 13:40~13:50 A novel pathway to prevent VSMC proliferation in neointimal hyperplasia ±èÀ±ÇÐ(ºÎ»ê´ë ÇغÎÇб³½Ç)

Åä·Ð 04-01 ÇѶóȦ Room2 13:50~14:30 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 14:30~14:50 New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 14:50~15:10 Anti-Inflammatory therapy for cardiovascular disease À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 15:10~15:30 wincretin (GLP-1/GIP dual agonist) for type 2 diabetes and obesity Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 15:30~16:00 Panel discussion ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 14:30~14:50 CV Risk assessment for lipid guidelines: current status & future perspective ÀÌÈ£±Ô(¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇб³½Ç)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 14:50~15:10 Emerging risk factors & biomarkers as CV risk enhancers ÀÌ´Ù¿µ(°í´ëÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room2 15:10~15:30 Coronary artery calcium score for CV risk reclassification ¿ÀÁø°æ(Ãæ³²ÀÇ´ë ½ÉÀå³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room2 15:30~16:00 Panel discussion ()

ÈÞ½Ä 04-01 ÇѶóȦ Room1 16:00~16:20 Coffee break ()

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 16:20~16:40 Pros Á¤¿µÈÆ(Áß¾ÓÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04-01 ÇѶóȦ Room1 16:40~17:00 Cons ±è½Å°ï(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04-01 ÇѶóȦ Room1 17:00~17:10 Rebuttal ()

Åä·Ð 04-01 ÇѶóȦ Room1 17:10~17:40 Panel discussion ()

±âŸ 04-01 ÇѶóȦ Room1 17:40~17:50 Closing remark ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (2023 SoLA of KSoLA) : 2023-04-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2023 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2023-04-02
´ÙÀ½±Û Áß¾Ó´ëÇб³º´¿ø Á¤½Å°Ç°­ÀÇÇаú 2023 Ãá°è¿¬¼ö±³À° ¡°¸ð¼º°ú Á¤½Å°Ç°­¡± : 2023-04-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
435 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ The 17th Postgraduate Course of Diabetes : 2018-09-15 0 845 2018-08-15
434 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-15 0 879 2018-08-15
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 963 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,514 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 970 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 771 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 632 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,483 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,551 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 512 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 514 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 801 2018-08-15
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 797 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 811 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷